Medical Research News and Research

RSS

Associated Press/Washington Post examine contributions of military research to reducing global disease burden

In light of the U.S. Army's announcement yesterday that an experimental HIV vaccine trial it is sponsoring in Thailand showed modest potential for preventing infection, the Associated Press/Washington Post examines how military research is contributing to the fight against major diseases around the world.

25 Sep 2009

PACTR: The first WHO endorsed trials registry in Africa

The Pan-African Clinical Trials Registry (PACTR) has been accepted as a primary clinical trials registry - the first World Health Organization (WHO) endorsed trials registry in Africa. This registry will feed data into the global WHO International Clinical Trials Registry Platform (ICTRP) search portal facilitating African representation in the global picture of planned, ongoing and completed clinical trials. The Registry is currently funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) and coordinated by the South African Cochrane Centre (SACC) at the Medical Research Council (MRC).

25 Sep 2009

NIH to award $348 million for investigators to speed the translation of research into improved health

The National Institutes of Health (NIH) announced today that it is awarding $348 million to encourage investigators to explore bold ideas that have the potential to catapult fields forward and speed the translation of research into improved health.

25 Sep 2009

Prevention and cure of Alzheimer's disease important to Americans

A new voter survey sponsored by the ACT-AD Coalition (Accelerate Cure/Treatments for Alzheimer's Disease) finds that three-quarters of Americans nationwide and across party lines say it is personally important to them to find a cure or to prevent Alzheimer's disease, while a similar proportion of the national electorate say they look to Congress to make it "a national priority" to speed up the Food and Drug Administration's (FDA) review process in specific ways for therapies that slow, halt or reverse the disease.

25 Sep 2009

Collaboration for the evaluation of peptide copolymer technology

Peptimmune, Inc., a privately held biotechnology company announced today that it has formed a research and development collaboration with the Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center (NMRC), Silver Spring, MD to evaluate the Company's proprietary DEEP(TM) peptide copolymer technology for the potential development of dengue vaccines and point-of-care diagnostics.

25 Sep 2009

Experimental HIV vaccine shows promise

An experimental HIV vaccine raises hope of reducing the risk of infection. Wall Street Journal/Associated Press reports: "For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. Recent failures led many scientists to think such a vaccine might never be possible."

25 Sep 2009

Liquidia founder Dr. Joseph DeSimone honoured with the NIH Director’s Pioneer Award

Liquidia Technologies today announced its founder, Dr. Joseph DeSimone, has received the National Institutes of Health (NIH) Director’s Pioneer Award. Pioneer Awards are designed to support individual scientists of exceptional creativity who propose pioneering – and possibly transforming – approaches to major challenges in biomedical and behavioral research.

24 Sep 2009

NIH awards three UNC Scientists for high risk and innovative research

Three scientists from the University of North Carolina at Chapel Hill School of Medicine and the UNC Lineberger Comprehensive Cancer Center have received prestigious awards from the National Institutes of Health (NIH) aimed at encouraging "high risk" and innovative research.

24 Sep 2009

NIH awards $2.5 million grant to University of Utah cardiologist

A pioneering model that a University of Utah cardiologist proposes as a cause of heart disease is the kind of creative thinking the National Institutes of Health (NIH) likes to see-and reward with one of its most prestigious honors, a $2.5 million 2009 Pioneer Award.

24 Sep 2009

Results of Phase 3 CRYSTAL study of mCRC patients announced

The retrospective CRYSTAL analysis was conducted as a result of an effort to increase the tissue ascertainment rate to determine the K-ras status of patients’ tumors. The analysis included extended patient follow up of nearly 1.5 years and doubled the tissue ascertainment rate from 45% to 89%. These data are an update from the overall survival results from CRYSTAL that were published in the April 2009 issue of the New England Journal of Medicine.

23 Sep 2009

AMRI's new research & development facility dedicated by Governor Christine Gregoire

AMRI (NASDAQ:AMRI) executives were joined by Governor Christine Gregoire in dedicating the company’s new research & development facility located in Bothell, WA. The company leased 44,000 square feet at 22215 26th Avenue SE with an option on an additional 40,000 square feet through Arden Realty, Inc. and invested approximately $8 million in fit-out costs and equipment.

23 Sep 2009

Vicor's PD2i heart-rate complexity metric to be tested on trauma patients in U.S. Army's C3E program

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Colonel Leopoldo Cancio of the U.S. Army Institute of Surgical Research (USAISR) identified its PD2i as a heart rate complexity metric that will be tested on trauma patients under the new Critical Combat Care Engineering (C3E) program.

23 Sep 2009

Gamma Medica-Ideas closes $24 million financing to support digital technologies

Gamma Medica-Ideas, Inc. ("GMI"), a leading developer of digital molecular imaging systems, announced today that it had closed a $24 million financing, the company's first institutional round, in order to support continued growth of the company's proprietary digital SPECT, PET and CT technologies in current and new markets.

23 Sep 2009

Novel cleavage sites for enzyme caspase-3 identified

Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.

22 Sep 2009

Junk DNA could accelerate development of gene therapies

Scientists have identified how a protein enables sections of so-called junk DNA to be cut and pasted within genetic code - a finding which could speed development of gene therapies.

21 Sep 2009

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.

21 Sep 2009

Swedish researcher to receive Fernström Foundation's Nordic Prize

Internationally renowned Swedish researcher Professor Jan-Åke Gustafsson, from KI and the University of Houston, is this year's recipient of the Fernström Foundation's Nordic Prize. The prize, which is worth SEK 1 million, is one of Scandinavia's most prestigious medical prizes.

21 Sep 2009

Research program to study personalized medicine

A new collaborative research program that will use the power of metabolomic profiling to help advance the concept of personalized medicine was announced September 17, 2009 by the Burnham Institute for Medical Research and the Sarah W. Stedman Nutrition and Metabolism Center at Duke University Medical Center.

18 Sep 2009

Zargis Medical receives FDA approval for marketing Signal X6 device

Zargis Medical Corp., a spin-off from Siemens Corporate Research and a majority-owned subsidiary of Speedus Corp., announced today it has received U.S. Food and Drug Administration (FDA) clearance to market its new Signal X6(TM) device.

18 Sep 2009

Book on the effects of antibiotic-resistant microbes

In RISING PLAGUE: THE GLOBAL THREAT FROM DEADLY BACTERIA AND OUR DWINDLING ARSENAL TO FIGHT THEM (Prometheus Books, $26), Dr. Brad Spellberg-an infectious diseases specialist and member of a national task force charged with attacking antibiotic resistant infections-tells the story of this potentially grave public health crisis.

18 Sep 2009

Medical Research News and Research

Associated Press/Washington Post examine contributions of military research to reducing global disease burden

PACTR: The first WHO endorsed trials registry in Africa

NIH to award $348 million for investigators to speed the translation of research into improved health

Prevention and cure of Alzheimer's disease important to Americans

Collaboration for the evaluation of peptide copolymer technology

Experimental HIV vaccine shows promise

Liquidia founder Dr. Joseph DeSimone honoured with the NIH Director’s Pioneer Award

NIH awards three UNC Scientists for high risk and innovative research

NIH awards $2.5 million grant to University of Utah cardiologist

Results of Phase 3 CRYSTAL study of mCRC patients announced

AMRI's new research & development facility dedicated by Governor Christine Gregoire

Vicor's PD2i heart-rate complexity metric to be tested on trauma patients in U.S. Army's C3E program

Gamma Medica-Ideas closes $24 million financing to support digital technologies

Novel cleavage sites for enzyme caspase-3 identified

Junk DNA could accelerate development of gene therapies

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

Swedish researcher to receive Fernström Foundation's Nordic Prize

Research program to study personalized medicine

Zargis Medical receives FDA approval for marketing Signal X6 device

Book on the effects of antibiotic-resistant microbes

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News